全球下呼吸道感染治疗市场 – 行业趋势及 2030 年预测

下呼吸道感染治疗市场分析及规模

肺炎是经常用来描述下呼吸道疾病的一个术语。流感、支气管炎、细支气管炎和肺炎是一些最常见的疾病，尽管它们并不都归为同一类别。在世界各地，下呼吸道感染是儿童和成人患病和死亡的主要原因。为了治疗患有急性呼吸窘迫综合征 (ARDS) 的危重患者，许多研究机构正在探索新的肺部治疗方法。

Data Bridge Market Research 分析，下呼吸道感染治疗市场在 2022 年为 502.2 亿美元，预计到 2030 年将达到 8957 万美元，在 2023 年至 2030 年的预测期内复合年增长率为 7.5%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

下呼吸道感染治疗市场范围和细分  

Market Definition

Infections that affect the airways (below the level of the larynx), such as the trachea and alveolar sacs, are referred to as lower respiratory tract infections (LRTI). LRTI can be categorized in several different ways. While pneumonia is an example of a severe infection that damages the alveolar sacs, severe infections that impact the airways include acute bronchitis, bronchiolitis, and the flu.

Lower Respiratory Tract Infection Treatment Market Dynamics

Drivers

• The rising prevalence of chronic respiratory disorders will drive the growth of the market

The rising prevalence of chronic respiratory disorders such as asthma, chronic pulmonary fibrosis, pulmonary hypertension, and occupational lung disease drive the respiratory tract infection market forward. For example, asthma and chronic obstructive pulmonary disease (COPD) are common chronic obstructive lung disorders characterized by variable airflow limitation and airway hyperresponsiveness. These are certain factors that will propel the market growth.

• The rise in the geriatric population will drive the market growth

The market's rise is anticipated to be aided by the growing geriatric population during the projection period of 2023-2030. The World Health Organization (WHO) projects that by 2050, there will be approximately 2 billion geriatric people globally, up from an estimated 524 million in 2010. Geriatrics are more likely to have lower respiratory tract infections because of their weakened immune systems, which is predicted to increase the market's growth rate.

Opportunities

• Collaborations and partnerships will act as an opportunity

Numerous organizations, institutions, and agencies are working together to enhance diagnostic and medical care to minimize the burden of respiratory illnesses on people worldwide. For instance, to fight chronic respiratory disorders, the World Health Organization (WHO) encouraged the creation of the Global Alliance against Chronic Respiratory Diseases (GARD). The primary objectives of GARD are to create simple and economic chronic respiratory disease (CRD) solutions and to persuade nations to undertake CRD prevention and health promotion measures. These are the certain reasons which will boost the market expansion.

Restraints/Challenges

• Side-effects associated with lower respiratory tract infection treatment

Overprescribing antibiotics is associated with a higher risk of adverse effects, frequent follow-up appointments, and a greater medicalization of self-limiting illnesses. Overprescribing antibiotics is a significant problem in primary care since viruses frequently cause infections. Almost 90% of all antibiotic prescriptions issued by general practitioners are for respiratory system infections.

This lower respiratory tract infection treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lower respiratory tract infection treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Biapenem was approved by the FDA for the treatment of intra-abdominal, lower respiratory, and severe urinary tract infections. Biapenem is typically given to patients with severe urinary tract infections, lower respiratory infections, or intra-abdominal infections. It's a parenterally administered carbapenem antibacterial medication. Biapen's dosage is considerably less than that of other carbapenems, though.

Global Lower Respiratory Tract Infection Treatment Market Scope

The lower respiratory tract infection treatment market is segmented on the basis of mode of transmission, type of infection, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mode of Transmission

• Hospital Acquired
• Ventilator Acquired
• Community Acquired

Type of Infection

• Pneumonia
• Bronchitis
• Influenza
• Tuberculosis
• Others

给药途径

• 口服
• 肠外
• 其他的

诊断

• 粘液样本
• 血液检查
• 胸部 X 光检查
• 脉搏血氧测定

治疗

• 药物
• 非甾体抗炎药 (NSAID)
• 对乙酰氨基酚
• 支气管扩张剂吸入器
• 抗生素
• 其他的
• 静脉输液
• 湿化氧气、疫苗
• 疫苗

最终用户

• 医院
• 专科诊所
• 家庭护理
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

下呼吸道感染治疗市场区域分析/见解

对下呼吸道感染治疗市场进行了分析，并按国家、传播方式、感染类型、诊断、治疗、给药途径、最终用户和分销渠道提供了市场规模见解和趋势。

下呼吸道感染治疗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美在下呼吸道感染治疗市场占据主导地位，因为该地区老年人口不断增长、免疫力低下的老年人以及年轻人感染多种耐药性细菌。重要关键参与者的存在和不断上涨的医疗成本将进一步促进该领域市场的快速扩张。

预计亚太地区将在 2023 年至 2030 年间以最高速度增长，因为不健康的生活方式在该地区变得越来越普遍。扩大医疗保健基础设施和提高患者意识也将推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和下呼吸道感染治疗市场份额分析

下呼吸道感染治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对下呼吸道感染治疗市场的关注有关。

下呼吸道感染治疗市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• 太阳制药工业有限公司 (印度)
• 默克公司（美国）
• 百时美施贵宝公司 (美国)
• 雅培（美国）
• Hikma Pharmaceuticals PLC（英国）
• 艾尔建（爱尔兰）
• 礼来公司 (美国)
• Aurobindo Pharma（印度）
• 鲁冰花（印度）
• 盐野义制药株式会社（日本）
• AbbVie Inc.（美国）

SKU-55897